Tevogen Bio Holdings Business Summary

Tevogen Bio Holdings Inc. (TVGN) is a clinical-stage immunotherapy company transitioning into a diversified healthcare enterprise through a unique "biotech-plus-services" model. The company generates revenue through the development and future commercialization of its proprietary ExacTcell™ platform, which produces off-the-shelf, genetically unmodified precision T-cell therapies for infectious diseases, oncology, and neurology. As of February 2026, Tevogen has expanded its revenue model by signing a Letter of Intent to acquire a majority stake in Sciometrix, integrating the Clinicus digital care management platform with its Tevogen.AI drug discovery initiative to provide remote patient monitoring and value-based care services. Its primary business segments include Tevogen Bio (therapeutic pipeline), Tevogen.AI (predictive drug development), and the newly integrated digital healthcare services. Tevogen competes directly with T-cell therapy developers such as Atara Biotherapeutics, TScan Therapeutics, and Alector, positioning itself as a cost-efficient disruptor by utilizing non-engineered T-cells to bypass the high costs and complexities associated with traditional CAR-T and CRISPR-based modalities. The company was founded by CEO Dr. Ryan Saadi, an expert in health policy and market access who previously led the Center for Market Access and Medical Innovation. The leadership team includes Chief Scientific Officer Dr. Neal Flomenberg, a pioneer in bone marrow transplantation and cellular immunology, and Chief Technical Officer Stephen Chen, who oversees the scalability of the ExacTcell™ platform. Other key executives include CFO Kirti Desai and Mittul Mehta, who heads the Tevogen.AI division. Tevogen is notable for its exceptionally high insider ownership, with executives and board members controlling over 74% of the company’s common stock. The Board of Directors features distinguished members such as Dr. Curtis Patton, Professor Emeritus at Yale School of Public Health, and Susan Podlogar, former Chief Human Resources Officer at MetLife with a background at Johnson & Johnson. Institutional backing includes positions from Portland Global Advisors, Geode Capital Management, and Polar Asset Management Partners.